PULM · Pulmatrix, Inc.
What's happening
- PULM is up 0.37% today, trading at $1.36. — Live quote
- Volume today (700) is well below its 3-month average of 43,320. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2025-03-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $6.0M | $4.7M | $16.8M | $25.6M | $24.9M |
| P/E | -1.30 | -0.87 | -2.46 | -2.18 | -2.66 |
| Price/Book | 2.35 | 1.31 | 3.54 | 4.57 | 3.49 |
| ROE | -181.23% | -150.54% | -144.12% | -209.76% | -131.26% |
| ROA | -142.76% | -120.24% | -136.91% | -191.08% | -116.52% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -122.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -70.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PULM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $366.0K | $1.6M | $5.9M |
| Operating income | -$1.0M | -$1.3M | -$866.0K | -$1.5M | -$1.8M | -$2.7M | -$5.9M | $747.0K |
| Net income | -$1.0M | -$1.2M | -$877.0K | -$1.5M | -$1.8M | -$2.6M | -$5.8M | $825.0K |
| EPS (diluted) | $-0.29 | $-0.32 | $-0.24 | $-0.42 | $-0.50 | $-0.71 | $-1.59 | $0.23 |
| EPS (basic) | $-0.29 | $-0.32 | $-0.24 | $-0.42 | $-0.50 | $-0.71 | $-1.59 | $0.23 |
| Operating margin | — | — | — | — | — | -$726 | -$380 | $13 |
| Net margin | — | — | — | — | — | -$707 | -$374 | $14 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $3.2M | $4.5M | $4.1M | $5.0M | $6.2M | $8.1M | $9.9M | $11.5M |
| Total liabilities | $689.0K | $905.0K | $329.0K | $249.0K | $548.0K | $904.0K | $996.0K | $590.0K |
| Stockholders' equity | $2.6M | $3.6M | $3.8M | $4.7M | $5.6M | $7.1M | $8.9M | $10.9M |
| Total current assets | $3.2M | $4.5M | $4.1M | $5.0M | $6.1M | $8.0M | $9.9M | $11.4M |
| Total current liabilities | $689.0K | $905.0K | $329.0K | $249.0K | $548.0K | $903.0K | $929.0K | $590.0K |
| Cash & equivalents | $2.2M | $3.3M | $4.1M | $4.8M | $5.8M | $7.7M | $9.5M | $10.8M |
| Accounts receivable | — | — | — | — | — | $16.0K | — | $23.0K |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | $13.0K | $54.0K |
| Accounts payable | $529.0K | $651.0K | $272.0K | $69.0K | $384.0K | $657.0K | $809.0K | $373.0K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$304.5M | -$303.5M | -$302.3M | -$301.4M | -$300.5M | -$299.0M | -$297.2M | -$295.2M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.1M | -$1.1M | -$706.0K | -$1.0M | -$1.9M | -$1.8M | -$1.3M | -$3.1M |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | -$50.0K | $1.0M | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | -$1.3M | -$3.1M |
| Capital expenditures | — | — | — | — | — | — | $0 | $0 |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Share-based compensation | $2.0K | $3.0K | $5.0K | $12.0K | $6.0K | $8.0K | $13.0K | $197.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | $16.0K | -$23.0K | -$612.0K |
| Change in accounts payable | -$122.0K | $379.0K | $203.0K | -$315.0K | -$273.0K | -$152.0K | $436.0K | -$20.0K |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $7.8M | $7.3M | $6.1M | $5.2M |
| Operating income | -$5.2M | -$9.8M | -$14.7M | -$18.9M | -$20.2M |
| Net income | -$5.2M | -$9.6M | -$14.1M | -$18.8M | -$20.2M |
| EPS (diluted) | $-1.41 | $-2.62 | $-3.87 | $-5.46 | — |
| EPS (basic) | $-1.41 | $-2.62 | $-3.87 | $-5.46 | $-8.63 |
| Operating margin | — | -$125 | -$202 | -$312 | -$390 |
| Net margin | — | -$122 | -$193 | -$310 | -$390 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $4.1M | $9.9M | $34.0M | $41.0M | $58.8M |
| Total liabilities | $329.0K | $996.0K | $16.0M | $9.8M | $11.4M |
| Stockholders' equity | $3.8M | $8.9M | $18.0M | $31.1M | $47.4M |
| Total current assets | $4.1M | $9.9M | $20.8M | $38.1M | $54.8M |
| Total current liabilities | $329.0K | $929.0K | $3.9M | $5.0M | $4.4M |
| Cash & equivalents | $4.1M | $9.5M | $19.2M | $35.6M | $53.8M |
| Accounts receivable | — | — | $928.0K | $1.3M | $67.0K |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | — | — | $1.2M | $235.0K | $321.0K |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | $13.0K | $176.0K | $389.0K | — |
| Accounts payable | $272.0K | $809.0K | $1.9M | $1.2M | $839.0K |
| Accrued liabilities | — | — | — | — | $1.2M |
| Deferred revenue (current) | — | — | $618.0K | $1.3M | $939.0K |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | — | — | — | — | — |
| Retained earnings | -$302.3M | -$297.2M | -$287.6M | -$273.5M | -$254.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.4M | -$10.7M | -$16.0M | -$19.4M | -$19.7M |
| Investing cash flow | — | -$398.0K | -$676.0K | -$86.0K | -$144.0K |
| Financing cash flow | — | — | $53.0K | $1.2M | $43.5M |
| Free cash flow | — | -$11.1M | -$16.7M | -$19.4M | -$19.9M |
| Capital expenditures | — | $398.0K | $676.0K | $86.0K | $144.0K |
| Depreciation & amortization | — | — | $134.0K | $162.0K | — |
| Share-based compensation | $25.0K | $511.0K | $954.0K | $1.1M | $1.2M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | — | -$928.0K | -$370.0K | $1.2M | -$17.0K |
| Change in accounts payable | -$537.0K | -$1.1M | $727.0K | $511.0K | -$149.0K |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PULM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:07 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-15 | View on SEC.gov → |
| 2026-04-21 | 8-K | 2026-04-16 | View on SEC.gov → |
| 2026-03-27 | 8-K | 2026-03-26 | View on SEC.gov → |
| 2026-03-02 | 8-K | 2026-02-28 | View on SEC.gov → |
| 2026-02-26 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-02-26 | 8-K | 2026-02-26 | View on SEC.gov → |
| 2025-12-18 | 8-K | 2025-12-17 | View on SEC.gov → |
| 2025-10-16 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-10-16 | 8-K | 2025-10-16 | View on SEC.gov → |
Recent news
Headlines about PULM (Pulmatrix, Inc.). Links open the publisher — we don’t host full articles.
-
MarketScreener lists USD 3.40 average target for Pulmonx stock
AD HOC NEWS · 2026-10-20 -
6 signs of pulmonary fibrosis to never ignore
The Irish News · 2026-10-20 -
What is pulmonary embolism? The serious blood clot condition sidelining Jalen Hurts
New York Post · 2026-10-19 -
Analysts set USD 3.50 target for Pulmonx stock, 96.63 percent above price
AD HOC NEWS · 2026-10-17 -
Pulmatrix, Inc. (2PU.F) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
Pulmonx stock has October 27, 2026 results date - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Yahoo Finance · 2026-09-22 -
Pulmatrix GAAP EPS of -$0.29
Seeking Alpha · 2026-08-13
No headlines in this category right now — try “All”.